Historical Valuation
Medtronic PLC (MDT) is now in the Undervalued zone, suggesting that its current forward PE ratio of 16.41 is considered Undervalued compared with the five-year average of 17.06. The fair price of Medtronic PLC (MDT) is between 103.84 to 127.68 according to relative valuation methord. Compared to the current price of 96.42 USD , Medtronic PLC is Undervalued By 7.15%.
Relative Value
Fair Zone
103.84-127.68
Current Price：96.42
7.15%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Medtronic PLC (MDT) has a current Price-to-Book (P/B) ratio of 2.53. Compared to its 3-year average P/B ratio of 2.25 , the current P/B ratio is approximately 12.53% higher. Relative to its 5-year average P/B ratio of 2.47, the current P/B ratio is about 2.62% higher. Medtronic PLC (MDT) has a Forward Free Cash Flow (FCF) yield of approximately 4.23%. Compared to its 3-year average FCF yield of 4.40%, the current FCF yield is approximately -3.96% lower. Relative to its 5-year average FCF yield of 4.19% , the current FCF yield is about 1.01% lower.
Competitors Valuation Multiple
AI Analysis
The average P/S ratio for MDT competitors is 5.91, providing a benchmark for relative valuation. Medtronic PLC Corp (MDT.N) exhibits a P/S ratio of 3.33, which is -43.72% above the industry average. Given its robust revenue growth of 6.64%, this premium appears unsustainable.
Performance Decomposition
AI Analysis
1Y
3Y
5Y
Market capitalization of MDT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MDT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is MDT currently overvalued or undervalued?
Medtronic PLC (MDT) is now in the Undervalued zone, suggesting that its current forward PE ratio of 16.41 is considered Undervalued compared with the five-year average of 17.06. The fair price of Medtronic PLC (MDT) is between 103.84 to 127.68 according to relative valuation methord. Compared to the current price of 96.42 USD , Medtronic PLC is Undervalued By 7.15% .
What is Medtronic PLC (MDT) fair value?
MDT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Medtronic PLC (MDT) is between 103.84 to 127.68 according to relative valuation methord.
How does MDT's valuation metrics compare to the industry average?
The average P/S ratio for MDT's competitors is 5.91, providing a benchmark for relative valuation. Medtronic PLC Corp (MDT) exhibits a P/S ratio of 3.33, which is -43.72% above the industry average. Given its robust revenue growth of 6.64%, this premium appears unsustainable.
What is the current P/B ratio for Medtronic PLC (MDT) as of Jan 14 2026?
As of Jan 14 2026, Medtronic PLC (MDT) has a P/B ratio of 2.53. This indicates that the market values MDT at 2.53 times its book value.
What is the current FCF Yield for Medtronic PLC (MDT) as of Jan 14 2026?
As of Jan 14 2026, Medtronic PLC (MDT) has a FCF Yield of 4.23%. This means that for every dollar of Medtronic PLC’s market capitalization, the company generates 4.23 cents in free cash flow.
What is the current Forward P/E ratio for Medtronic PLC (MDT) as of Jan 14 2026?
As of Jan 14 2026, Medtronic PLC (MDT) has a Forward P/E ratio of 16.41. This means the market is willing to pay $16.41 for every dollar of Medtronic PLC’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Medtronic PLC (MDT) as of Jan 14 2026?
As of Jan 14 2026, Medtronic PLC (MDT) has a Forward P/S ratio of 3.33. This means the market is valuing MDT at $3.33 for every dollar of expected revenue over the next 12 months.